Focus Point Holdings Berhad

KLSE:FOCUSP Stock Report

Mkt Cap: RM247.5m

We’ve recently updated our valuation analysis.

Focus Point Holdings Berhad Valuation

Is FOCUSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FOCUSP?

Other financial metrics that can be useful for relative valuation.

FOCUSP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA5.7x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does FOCUSP's PE Ratio compare to its peers?

The above table shows the PE ratio for FOCUSP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average36.5x
CENGILD Cengild Medical Berhad
32xn/aRM372.6m
KPJ KPJ Healthcare Berhad
34.7x17.3%RM4.2b
OPTIMAX Optimax Holdings Berhad
24.6x12.4%RM396.9m
MHCARE Metro Healthcare Berhad
54.5xn/aRM419.4m
FOCUSP Focus Point Holdings Berhad
7.1x3.7%RM247.5m

Price-To-Earnings vs Peers: FOCUSP is good value based on its Price-To-Earnings Ratio (7.1x) compared to the peer average (36.5x).


Price to Earnings Ratio vs Industry

How does FOCUSP's PE Ratio compare vs other companies in the Asian Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.2%
n/an/an/a

Price-To-Earnings vs Industry: FOCUSP is good value based on its Price-To-Earnings Ratio (7.1x) compared to the Asian Healthcare industry average (19.3x)


Price to Earnings Ratio vs Fair Ratio

What is FOCUSP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FOCUSP PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.1x
Fair PE Ratio8.7x

Price-To-Earnings vs Fair Ratio: FOCUSP is good value based on its Price-To-Earnings Ratio (7.1x) compared to the estimated Fair Price-To-Earnings Ratio (8.7x).


Share Price vs Fair Value

What is the Fair Price of FOCUSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: FOCUSP (MYR0.75) is trading below our estimate of fair value (MYR3.23)

Significantly Below Fair Value: FOCUSP is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FOCUSP forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentRM0.75
RM1.55
+106.7%
2.6%RM1.59RM1.51n/a2
Nov ’23RM0.72
RM1.55
+113.8%
2.6%RM1.59RM1.51n/a2
Oct ’23RM0.73
RM1.55
+110.9%
2.6%RM1.59RM1.51n/a2
Sep ’23RM0.73
RM1.49
+102.7%
6.7%RM1.59RM1.39n/a2
Aug ’23RM0.71
RM1.31
+83.2%
2.3%RM1.34RM1.28n/a2
Jul ’23RM0.76
RM1.31
+73.5%
2.3%RM1.34RM1.28n/a2
Jun ’23RM0.78
RM1.19
+53.5%
14.4%RM1.34RM0.95n/a3
May ’23RM0.79
RM1.08
+38.0%
9.0%RM1.18RM0.95n/a3
Apr ’23RM0.74
RM1.08
+46.4%
9.0%RM1.18RM0.95n/a3
Mar ’23RM0.76
RM1.08
+42.5%
9.0%RM1.18RM0.95n/a3
Feb ’23RM0.69
RM1.00
+45.4%
3.8%RM1.03RM0.95n/a3
Jan ’23RM0.64
RM1.00
+58.0%
3.8%RM1.03RM0.95n/a3
Dec ’22RM0.66
RM1.00
+52.0%
3.8%RM1.03RM0.95n/a3
Nov ’22RM0.75
RM1.00
+33.8%
3.8%RM1.03RM0.95RM0.723
Oct ’22RM0.74
RM1.03
+39.2%
0%RM1.03RM1.03RM0.732
Sep ’22RM0.73
RM1.03
+40.1%
0%RM1.03RM1.03RM0.732
Aug ’22RM0.74
RM1.04
+40.5%
1.0%RM1.05RM1.03RM0.712
Jul ’22RM0.74
RM1.04
+39.6%
1.0%RM1.05RM1.03RM0.762
Jun ’22RM0.77
RM1.07
+39.2%
3.3%RM1.10RM1.03RM0.782
May ’22RM0.82
RM1.07
+30.5%
3.7%RM1.11RM1.03RM0.792
Apr ’22RM0.79
RM0.93
+17.8%
20.0%RM1.11RM0.74RM0.742
Mar ’22RM0.83
RM0.93
+11.4%
20.0%RM1.11RM0.74RM0.762
Feb ’22RM0.89
RM0.59
-33.1%
14.6%RM0.68RM0.51RM0.692
Jan ’22RM0.64
RM0.59
-7.3%
14.6%RM0.68RM0.51RM0.642
Dec ’21RM0.53
RM0.56
+7.0%
10.1%RM0.62RM0.51RM0.662
Nov ’21RM0.38
RM0.55
+42.6%
7.3%RM0.59RM0.51RM0.752

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies